RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.

Detailed results of the vote for the election of directors are set out below:

Name of Nominee	Votes For	% Votes For		Votes Withheld	% Votes Withheld
Dr. Khalid Islam	13,858,131	97.84	%	304,760	2.15	%
Mr. Chris A. Rallis	13,808,792	97.49	%	354,099	2.50	%
Mr. Marco Brughera	13,807,501	97.49	%	355,390	2.50	%
Dr. Jodi Cook	13,259,894	93.62	%	902,997	6.37	%
Mr. Jeff Hackman	13,495,309	95.28	%	667,582	4.71	%

Shareholders voted 99.64% in favor of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 85.50% in favor of the compensation paid to the Company's named executive officers, and 91.27% (88.01% after subtracting shares held by insiders eligible to participate in the Company's 2020 Equity Incentive Plan) in favor of certain amendment to the Company's 2020 Equity Incentive Plan.

The Company has relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, in the approval of the amendments to its 2020 Equity Incentive Plan.

For further information, please contact:

Robert Andrade

Chief Financial Officer

Fennec Pharmaceuticals Inc.

Tel: 919-246-5299